SUBJECT INDEX

Acetate
  cardiovascular effects, 221, 230
  clinical comparison of acetate and bicarbonate dialysis, 195, 335
dialysate, effect on aluminium dialysate, 336
dialysate, effect on potassium removal, 209
  experience in elderly dialysis patients, 503, 507, 511
  metabolic effects during dialysis, 230
  phosphate dialysate, 215
Acidosis
  effect on muscle intracellular acid/base status, 881
  hyperchloraemic hyperkalaemia in diabetic nephropathy, 801
Acute renal failure, see Renal failure, acute
Adenosine, in Belzer II solution for renal preservation for transplantation, 1027
Adrenaline, effect of dialysate sodium, 225
Adrenergic receptors, on lymphocytes in haemodialysis patients, 178
Afferent arteriole, spasm in cyclosporine nephrotoxicity, 853
Age, haemodialysis in elderly patients, 490
Albumin, excretion in diabetic nephropathy, 633, 875
Albumin excretion, relation in dietary protein, 551
Alcohol
  injection into parathyroid glands to control hypercalcaemia, 895
  reversible tubular dysfunction in alcoholic patients, 866
Aldosterone
  effect of captopril on plasma values, 820
  in pregnancy induced hypertension, 808
  response to potassium changes in essential hypertension, 815
ALG, improved graft survival rates with cyclosporine therapy, 987
Alpha-tocopherol, see Vitamin E
Aluminium
  absorption mechanism in chronic renal failure, 354
  associated bone disease, 415
  bone scans, 403
desferrioxamine removal by haemodialysis, 366
desferrioxamine treatment, 403
DFO test as a predictor of bone aluminium, 371
  removal by DFO, 382
effect of aluminium hydroxide on anaemia, 410
effects of biochemical measurements on bone histology, 415
effect on bone scintigraphy, 399
effect of dialysate buffer on removal, 366
effect on erythropoiesis, 395
effect of 1αOH₂D₃ on plasma aluminium concentration, 390
effect of pre-existing bone pathology on uptake, 387
hyperparathyroidism, 403
  interaction with iron absorption, 354, 410
  osteomalacia, 415
  protein binding in chronic renal failure, 360
  relationship to plasma ferritin, 354
  removal by DFO, 382
  removal by DFO and haemodialysis or haemofiltration, 371, 469
water treatment, 111
Aluminium associated bone disease bone scintigraphy, 399
desferrioxamine treatment, 403
PTH values, 403
use of bone scan, 403
Amyloid, in patients after prolonged haemodialysis, 291
Amyloidosis
  colchicine treatment in familial Mediterranean fever, 709
  familial nephropathic, 683
Anaemia
  deterioration due to excessive water nitrates, 321
  role of aluminium hydroxide, 410
  role for vitamin E, 296
Analgesic nephropathy, morbidity in haemodialysis patients, 311
Anaphylaxis, during haemodialysis due to ethylene oxide hypersensitivity, 175
Anti-streptococcal antibodies, in IgA nephropathy, 698
Autonomic neuropathy, effect of naloxone, 190
β Microglobulin, in diabetic patients, 649
urinary excretion in alcoholic patients, 866
Bacteria, contamination in water, 122
Bacteriological monitoring, on-line haemofiltration fluid, 454
Bicarbonate
clinical comparison of acetate and bicarbonate dialysis, 195, 335
dialysate, effect on aluminium dialysance, 209
dialysate, effect on potassium removal, 215
phosphate dialysance, 215
Bioocompatibility, 99, 104
haemodynamic response to sham dialysis, 156
importance of blood lines, 162
Blood flow, in AV grafts, 262
Blood lines, bioocompatibility studies, 162
Body mass index, Registry Statistics, 43
Bone
aluminium content, 371
biopsy in patients using fluoridated dialysate, 421
fluoride content in osteodystrophy, 421
histology in aluminium associated bone disease, 415
mineral loss during haemodialysis, 435
scans in aluminium-associated bone disease, 403
scintigraphy in dialysis osteodystrophy, 431
Bone scintigraphy
effect of aluminium, 399
effect of hyperparathyroidism, 399
in renal osteodystrophy, 431
Calcium metabolism
in Fanconi syndrome, 751
magnesium depletion in idiopathic hypercalciuria, 747
Calcium stone disease
magnesium depletion from renal loss, 747
treatment by high fluid intake or diuretics, 743
CAPD
effect on left ventricular anatomy, 185
experience in patients with diabetic nephropathy, 330
causes of death in elderly patients, 499
in children, 82–84
platelet life span, 306
rehabilitation in elderly patients, 496
results of transplantation, 932
timing of catheter removal after transplantation, 932
Captopril
effect on experimental acute renal failure, 843
effect on plasma aldosterone, 808
effect on urinary prostaglandin excretion, 808
Carbon filtration, water treatment, 115
Cardiovascular
acetate effects, 221, 230
CAPD and after transplantation, 185
changes during experimental acute renal failure, 837
changes in left ventricular anatomy during haemodialysis, 230
elderly dialysis patients, 500, 512
haemodynamic response to sham dialysis, 156
myocardial studies in haemodialysis patients, 251
risk factors in dialysis patients, 202
succinate effects, 230
tolerance during haemodialysis in elderly patients, 503
Carpal tunnel syndrome, in patients after prolonged haemodialysis, 291
Catecholamines
effect of dialysate sodium, 225
response to exercise in haemodialysis patients, 178
Children
growth on chronic renal failure, 830
growth on haemofiltration dependent on adequate treatment, 326
urinary protein excretion in diabetes mellitus, 638
Chloramne, removal by carbon filters, 115
Chlorine, removal by carbon filters, 115
Chronic renal failure, see Renal failure, chronic
Chronic rejection, association with graft membranous nephropathy, 672
Cimetidine
effect on experimental renal autoregulation, 765
effect on renal function, 761
Cirrhosis, HBsAg negative complicated by vasculitis and renal involvement, 677
Clearance studies, of phosphorus during haemodialysis or haemofiltration, 461
Coagulation
during dialysis with heparin coated dialysers, 270
during dialysis with low molecular weight heparin, 276
effect of eosinophilia on heparin action, 143
prostacyclin haemodialysis, 281
Colchicine, treatment in familial Mediterranean fever, 709
Computerised tomography, 784
Computers, in renal units, 61
Computer studies, clinical comparison of acetate and bicarbonate dialysis, 335
Copper
in haemodialysis patients, 247
liberation from dialysate membrane, 247
Coronary artery disease, in haemodialysis patients, 251
Cortisol, response to potassium changes in essential hypertension, 815
Crescentic glomerulonephritis, 973
Cyclic AMP, effect of ranitidine on urinary excretion, 761
Cryoglobulinaemia, in cirrhosis with vasculitis, 677, 527
Cuprophan
effect of eosinophilia on the anticoagulant response to heparin, 143
in an experimental dialysate membrane reaction, 135
Cyclosporine
acute renal failure, 849
change in plasma lipids, 1010
CMV infection, 1021
conversion from conventional therapy, 982
conversion to conventional therapy, 992, 998, 1010
distribution volume, 1002
drug interference with plasma measurements, 959
effect on outcome of cadaveric renal transplantation, 963
gastrointestinal absorption, 1002
improved graft and patient survival rates with ALG, 987
incidence of early acute rejection episodes, 987
inhibition of renal prostaglandin synthesis, 853, 947, 969, 973, 992, 998
in combination with ATG used sequentially, 982
in combination with prednisolone, 963
influence of renal failure on cyclosporine blood levels, 1002
influence on prednisolone pharmacokinetics, 963
in renal transplantation, 982, 998
interaction with sulphinpyrazone, 1021
lithium clearance studies, 853
lymphoma and lymphoproliferative disorders, 1021
metabolic effects of conversion to conventional immunosuppression, 1010
micropuncture studies, 853
monoclonal antibodies, 1042
nature killer cells, 1042
pharmacokinetics, 948
plus steroids in renal transplantation, 998
Registry Statistics, 33
renal function tests, 992
thromboxane B2 and beta2-microglobulin during graft rejection, 1032
treatment protocols, 982, 992
Cyclosporine nephrotoxicity
aetiology, 853
afferent arteriole spasm, 853
chronic, 954
clinical classification, 948
effective renal plasma flow, 992
enhanced in hepatic failure, 948
influence of pre-operative effective renal plasma flow, 973
in heart and heart-lung graft recipients, 973
interaction with other drugs, 951
morphology, 948, 954
subcapsular pressure monitoring, 954
Cytomegalovirus infection
after transplantation, 936
in haemodialysis patients, 317
pneumatisis intestinalis, 936
Deionisation, water treatment, 117
Desferrioxamine
aluminium removal by haemodialysis, 366, 377, 382, 403
changes in serum aluminium, 360
effect on aluminium in experimental osteomalacia, 387
effect of therapy on erythropoiesis, 394
iron removal by haemodialysis and
by haemofiltration, 377, 382
test to predict bone aluminium, 371
treatment of aluminium-associated
bone disease, 403
Diabetes insipidus, tubular ultrastructural
changes in an experimental model, 732
Diabetes mellitus
cardiovascular risk factors in dialysis
patients, 202
effect of naloxone on the Valsalva
manoeuvre, 190
experience with patients on CAPD, 330
experimental studies of ureteric
ligation, 860
factors producing nephropathy, 642
glycosylated proteins, 649
renal donors for transplantation, 655
transplantation, 31
treatment by continuous subcutaneous
insulin infusions, 722
urinary protein excretion as a marker
of early nephropathy, 638
Diabetic nephropathy, 621
early renal functional change, 623
glycosylated proteins, 649, 873
hyperchloraeic, hyperkalaemic
acidosis, 801
hypoadosteronism, 801
hyporeninaemia, 801
insulin pump treatment, 622
low incidence of hyperparathyroidism, 902
management, 611, 621, 626
microalbuminuria, 625
renal tubular acidosis, 801
role of RPF and GFR in nephropathy, 642
treatment by continuous subcutaneous
insulin infusions, 722
tubular and glomerular proteinuria
in hyperosmolar states, 875
urinary albumin excretion, 625, 633,
875
urinary protein excretion, 638
Diagnostic procedures, thallium-201
scintigraphy, 251
Dialysate
cardiovascular and metabolic effect
of acetate and succinate dialysate, 230
clinical comparison of acetate and
bicarbonate dialysis, 195, 335
effect of buffer on aluminium
removal, 209, 366
effect of sodium concentration on
dopamine, adrenaline and nor-
adrenaline, 225
effect of temperature on leukopenia,
167
water preparation, 111–128
Dialysers
coupling studies, 143
efficiency of a high flux haemodialfiltration, 447
experimental experience with heparin
coating, 270
high flux dialysers, 366
leaching of substances, 104
reactions, 97–107
re-use, 103
Dialyser reactions, 105
due to IgE antibody to albumin, 173
Dialysis
phosphate kinetics, 215
use of the biocarbon vascular access
device for haemodialysis, 267
volume changes with hypertonic
haemodialysis fluid, 235
Dialysis equipment, 56–61
Dialysis tubing, silicone spallation, 287
Diet, effect of protein restriction on
progression of renal failure, 549, 561,
600, 604, 622
Digital vascular imaging, 783
Distillation, water treatment, 121
Diuretic therapy, thiazide in recurrent
calcium stone formers, 743
Donor nephrectomy
complications of nephrectomy in the
donor, 267
incidence of hypertension in living
related donors, 911
influence of nephrectomy on GFR
and blood pressure following living
donor transplantation, 574
Dopamine, effect of dialysate sodium,
225
Echocardiography, in assessing left
ventricular anatomy, 185
Effective renal plasma flow, in cyclo-
sporine treated patients, 992
Eosinophilia
effect on the anticoagulant action of
heparin, 143
in biocompatibility studies, 162
seasonal variation, 162
Epstein-Barr, infections in haemodialysis
patients, 317

1050
Erythropoiesis, inhibition by aluminium, 394

Essential hypertension
  aldosterone response to potassium changes, 815
  cortisol response to potassium changes, 815
  renin response to potassium changes, 815

Essential mixed cryoglobulinaemia, 527
  clinical manifestations, 534
  pathogenesis of renal damage, 545
  renal histology, 528
  treatment, 541

Extracellular matrix, in glomerular sclerosis, 801

Fabry's disease, immune function, 686

Familial Mediterranean fever, colchicine treatment and effect on amyloid, 709

Familial nephropathic amyloidosis, 683

Familial renal disease, in partial HPRT deficiency, 751

Fanconi syndrome, vitamin D metabolism and bone disease, 756

Fc receptor function and glomerulonephritis, 661

Ferritin
  as a stimulus to experimental IgA nephropathy, 703
  influence on aluminium absorption, 354
  in predicting iron removal by haemodialysis or haemofiltration, 469

Filtration fraction
  in SLE nephropathy, 717
  single shot clearance technique, 717

Fine needle aspiration biopsy, Registry Statistics, 33

Fistulae, see Vascular access

Fluoride, in renal osteodystrophy, 421

Focal sclerosing glomerulonephritis, 792

Furosemide, effects on sodium reabsorption in Henle's loop during maximal antidiuresis, 738

Glomerular C3b receptors, in renal allografts, 1015

Glomerular cells, metabolism, 793, 794, 795

Glomerular extracellular matrix composition, 792
  source, 793

Glomerular filtration rate
  effect of cimetidine, 765
  in cyclosporine nephrotoxicity, 853
  in diabetic nephropathy, 642

Radiolabelled tests, 775

Glomerulonephritis
  anti-streptococcal antibodies in IgA nephropathy, 698
  crescentic, 793
  diffuse proliferative in cirrhosis with vasculitis, 677
  effect on dietary protein restriction, 500
  essential mixed cryoglobulinaemia, 527
  experimental IgA nephropathy, 703
  Fc receptor function, 661
  focal necrotising in cirrhosis with vasculitis, 677
  focal sclerosing, 792
  hypertension in IgA nephropathy, 693
  IgA nephropathy, 693
  immune function in Fabry's disease, 686
  in HBsAg negative cirrhosis with vasculitis, 677
  interstitial foam cells, 666
  macrophage function, 661
  minimal lesion in adults, 588
  reticuloendothelial blockade, 661
  role of immune complexes, 661
  systemic lupus erythematosus, 712, 717
  therapy by steroids or plasma exchange in crescentic GN, 594
  therapy in minimal lesion in adults, 588

Glomerulosclerosis
  in vitro studies, 791
  involvement of normal extracellular matrix, 791
  pathogenesis, 791
  role of cellular components, 791
  role of interleukin 1, 791

Glucose metabolism, insulin resistance in uraemia, 725

Glycosylated albumin, urinary excretion in diabetic nephropathy, 635, 875

Glycosylated proteins, diabetic patients, 649

Gonadotrophin, effect of naloxone infusion in chronic renal failure, 608

Gout, in partial HPRT deficiency, 751

Growth
  in children, 90–93
  in children with chronic renal failure, 830

Gut hormones, in chronic renal failure, 614

1051
H₂-receptor blockers
  effect on renal function and para-
throid activity, 761
  effect on experimental renal auto-
regulation, 765
Haemodialysis
  acetate, 195, 209, 215, 230, 335, 366
  alternatives to fistulae for vascular
access, 257
  aluminium and iron removal after
desferrioxamine, 469
  aluminium removal by DFO, 366,
  377, 382, 403
  amyloid deposition as a long term
 complication, 291
  anaemia and aluminium toxicity, 394
  anaemia due to nitrates, 321
  bicarbonate, 195, 335
  bone mineral loss, 435
  bone scintigraphy for the investi-
gation of osteodystrophy, 394, 431
  cardiovascular effects of acetate and
succinate dialysate solutions, 230
  cardiovascular risk factors in diabetic
and non-diabetic patients, 202
  carpal tunnel syndrome, 291
  cause of death in elderly patients,
  499, 513
  changes in plasma intracellular and
extracellular volumes, 235
  children, 80, 82
  clinical comparison of acetate and
bicarbonate dialysis, 195
  copper and zinc kinetics, 247
  effect of dialysate buffer on potas-
sium removal, 209
  effect of eosinophilia on the anti-
coagulant response to heparin, 143
  effect of 1αOHD₃ on plasma aluminium,
  390
  effect on left ventricular anatomy,
  185
  effect of naloxone on the Valsalva
manoeuvre, 190
  effect of temperature on leukopenia,
  167
  experience in elderly patients, 477,
  490, 510
  experience with hypertonic haemo-
dialysis, 235
  experimental experience with heparin
coated dialysers, 270
  experience with low molecular
weight heparin, 276
  fluoride metabolism, 421
  growth in children, 830
  haemodynamic response to sham
dialysis, 156
  hepatitis B vaccination schedules,
  300
  high flux dialysers, 366
  importance of blood lines in biocom-
patibility studies, 162
  iron removal by DFO, 377, 382
  lymphocyte β₂-adrenoceptors, 12
  myocardial studies, 251
  morbidity in patients with analgesic
nephropathy, 311
  patient selection, 490
  phosphorus kinetics, 461
  plasma catecholamine response to
exercise, 178
  platelet life span, 306
  prostacyclin, 281
  protein binding of aluminium, 360
  rehabilitation in elderly patients, 496
  reactions due to ethylene oxide, 173
  removal of aluminium by DFO, 366
  shoulder pain syndrome, 291
  silicone spillation, 287
  transfer of nickel from dialysate, 241
  virus infections, 317
  vitamin E supplementation, 296
  water preparation, 111–128
  water quality, 122
Haemodynamic factors in diabetic
nephropathy, 642
Haemofiltration
  aluminium and iron removal after
desferrioxamine, 469
  aluminium removal by DFO, 382
  experience in elderly patients, 510
  experience with low molecular
weight heparin, 276
  iron removal by DFO, 377, 382
  nitrogen balance to determine
adequacy of treatment in children,
  326
  on-line preparation of substitution
fluid, 454
  phosphorus kinetics, 461
  sieving coefficient, 101
  technique without substitution fluid,
  441
  water quality, 124
Haemosiderosis, treatment by DFO in
haemodialysis patients, 382
Heart transplantation, incidence of
cyclosporine nephrotoxicity after
cardiac transplantation – comparison
with heart-lung transplantation, 973
Hemastite vascular access device, 262
Heparin
alteration of action by eosinophilia, 143
experimental experience with heparin coated dialysers, 270
low molecular weight in haemodialysis and haemofiltration, 276
Hepatic failure, Registry Statistics, 47
Hepatitis, Registry Statistics, 51
Hepatitis B, vaccination in patients with renal failure, 300
Herpes simplex, infection in haemodialysis patients, 317
Herpes zoster, infection in haemodialysis patients, 317
Hippuran clearance, 773
Hospitalisation, elderly dialysis patients, 497, 507, 515
Human pancreatic polypeptide (HPP), in chronic renal failure and dialysis, 614
Hypercalcaemia, control by parathyroid alcohol injection, 895
Hypercalciuria, effect of fluid or diuretics on recurrent stone formation, 743
Hyperparathyroidism
and aluminium-associated bone disease, 403
bone scans, 403
effect on bone scintigraphy, 399
effects of parathyroidectomy, 888
in chronic renal failure, 888
incidence of ectopic calcification, 888
in diabetic renal failure, 902
intact assay system in assessing parathyroid hormone, 426
secondary treatment by ultrasonically guided fine-needle alcohol injection, 895
Hypertension
captopril induced, 820
developing in kidney donors, 580
essential mixed cryoglobulinaemia, 540
IgA nephropathy, 693
incidence after donor nephrectomy for transplantation, 911
in diabetic patients on CAPD, 330
pregnancy induced, 808
prognostic indicator in diabetic nephropathy, 626
Hyperuricosurias, effect of fluid or diuretics on recurrent stone formation, 743
Hypoxia, experimental dialyser membrane reaction, 135
Hypoxanthine-guanine phosphoribosyltransferase, partial deficiency causing acute renal failure in an infant, 751
Idiopathic hypercalciuria, magnesium depletion, 747
IgA nephropathy
experimental studies, 703
hypertension, 693
antistreptococcal antibodies, 698
IgE, antibodies to albumin exposed to ethylene oxide, 173
Immune complex
in experimental IgA nephropathy, 703
in primary and secondary glomerulonephritis, 661
Immune responsiveness, in Fabry's disease, 686
Immunoglobulins
essential mixed cryoglobulinaemia, 528
in experimental IgA nephropathy, 703
in Fabry's disease, 686
Indomethacin
effect in experimental dialysate membrane reactions, 135
effect on natriuresis during captopril therapy, 820
Inflammation, effect of mediators on isolated glomerular cells, 793
Insulin
continuous subcutaneous infusion and effect on proteinuria and renal function, 722
resistance in uraemia, 725
Interleukin 1
and endothelial growth, 791
in zinc deficiency in chronic renal failure, 825
Interleukin 2, production capacity during allograft rejection, 1006
Interstitial foam cells, in the nephrotic syndrome, 666
Intrarenal blood flow, 774
Iron
removal by DFO, 382
removal by DFO and haemodialysis or haemofiltration, 469
Kallikrein, in pregnancy induced hypertension, 808
Keto-acids, influence on progression of renal failure, 561
Leaching, from dialysers, 104
Leukopenia
 experimental mode for dialyser membrane reactions, 135
temperature dependent during dialysis, 167

Lithium clearance, in cyclosporine nephrotoxicity, 853

Lipids, changes following cyclosporine conversion, 1010

Lymphocyte adrenergic receptors, in HD patients, 178

Lymphocyte function, in Fabry’s disease, 686

Lymphoproliferative disorders
 in CMV infection, 1021
 in cyclosporine treated patients, 1021

Macrophages, renal interstitial in the nephrotic syndrome, 666

Macrophage function, in primary and secondary glomerulonephritis, 661

Magnesium, renal loss in calcium stone formers, 747

Malignancy, in transplant recipients, 1021

Malignant disease, Registry Statistics, 47

Malonyldialdehyde, in the measurement of platelet survival, 306

Membranes, 99
 ethylene oxide hypersensitivity, 173
 experimental model for dialyser membrane reactions, 135
 for reverse osmosis, 119
 haemodynamic response to sham dialysis, 156
 interaction between neutrophils and cuprophan membranes, 150
 liberation of copper and zinc, 247

Membrane filtration, bacteriological monitoring of on-line fluid preparation, 454

Membraneous nephropathy
 in association with chronic renal allograft rejection, 672
 role of HLA compatibility, 672

Mesangial cells, metabolism, 794

Mesangiocapillary glomerulonephritis,
 essential mixed cryoglobulinaemia, 530

Metastatic calcifications
 effect of parathyroidectomy, 888
 incidence after parathyroidectomy, 888

Middle molecules, 100

Monoclonal antibodies
 studies in renal biopsies from patients with the nephrotic syndrome, 666
 monocytes after blood transfusion, 923
 studies in allograft renal biopsies, 1015
to NK cells, 1042
to T cell subsets, 1037

Monocytes
 essential mixed cryoglobulinaemia, 531
 function in zinc deficiency in chronic renal failure, 825
 PGE and thromboxane release after blood transfusion, 923
 renal interstitial in the nephrotic syndrome, 666

Muscle, intracellular buffering in acidosis, 881

Myocardial function, in haemodialysis patients, 251

Naloxone, effect on the Valsalva manoeuvre in dialysis patients, 190

Natural killer cells
 in Fabry’s disease, 686
 monoclonal antibodies, 1042
 transplantation, 1042

Neopterine, urinary excretion in rejection, 951

Nephrotic syndrome
 interstitial foam cells, 666
 response in adults to steroid therapy, 588

Neutrophils, interaction with cuprophan membranes, 150

Nickel, serum concentrations in chronic renal failure, 241

Nitrates, excess amounts in water aggravating anaemia, 321

Nitrogen balance, in haemofiltration in children, 326

Nitrosodimethylamine, from deioniser effluent, 119

Noradrenaline, effect of dialysate sodium, 225

Nuclear magnetic resonance, 785

Osteitis fibrosa cystica
 effects of parathyroidectomy, 888
 incidence in chronic renal failure, 888

Osteomalacia
 bone aluminium 371
 bone uptake of aluminium in an experimental study, 387

Paediatric patients, see Children

1054
Parathormone
  influence on bone turnover, 415
  osteoblastic/osteoclastic surfaces, 415
Parathyroid autograft, evaluation of intact assay system in studying function, 426
Parathyroid hormone
  effect of ranitidine therapy, 761
  evaluation of intact assay system in studying autograft function, 426
  status in relation to bone mineral loss, 435
Parathyroidectomy
effect on osteitis fibrosa cystica, 888
  Registry Statistics, 50, 93
Pericarditis, elderly dialysis patients, 497, 512, 515
Peritonitis, elderly dialysis patients, 497, 512, 515
Phosphate
  effect of ranitidine in urinary excretion, 761
  regulation in body fluid, 461
  removal during acetate and bicarbonate dialysis, 215
Phosphate binders
  aluminium absorption, 354
  effect of change in policy on anaemia and plasma phosphate, 410
  iron absorption, 354
Phosphate metabolism, in diabetic patients with chronic renal failure, 902
Phosphorus, influence on progression to renal failure, 561
Phosphorus kinetics, in haemodialysis and haemofiltration, 461
Plasma exchange
  essential mixed cryoglobulinaemia, 541
  in rapidly progressive crescentic glomerulonephritis, 594
Platelets
  derived growth factor and endothelial growth, 791
  prostacyclin haemodialysis, 281
  survival in uraemia, haemodialysis and CAPD, 306
Pneumatosiis intestinalis, association with CMV infection after transplantation, 936
Potassium, effect of dialysate buffer on removal, 209
Polycrylonitrile, effect of eosinophilia on the anticoagulant response to heparin, 143
Polycations, role in the progression of renal failure, 549
Polycythaemia
  after transplantation, 928
  erythropoietin sensitivity of erythroid precursors in post-transplant polycythaemia, 928
Polyserositis, in familial nephropathic amyloidosis, 683
Prednisolone pharmacokinetics
  effects of anti-tuberculous therapy, 963
  effects of cyclosporine, 963
  influence on outcome of transplantation, 963
Pregnancy
  hypertension, 808
  Registry Statistics, 56
Prolactin, effect of naloxone infusion in chronic renal failure, 608
Propranolol, effect on experimental acute renal failure, 843
Prostacyclin, haemodialysis, 281
Prostaglandin
  inhibition of synthesis by cyclosporine, 969
  in pregnancy induced hypertension, 808
  role in cyclosporine nephrotoxicity, 984
  urinary excretion after captopril therapy, 820
Prostaglandin E, role in the transfusion effect on transplantation, 923
Protein catabolic rate, in haemofiltration in children, 326
Protein restriction, effect on progression to renal failure, 561, 567
Proteinuria
  after donor nephrectomy, 580
  albumin excretion in diabetic nephropathy, 633
  diabetic nephropathy, 638, 642
  effect of continuous subcutaneous infusion in diabetic nephropathy, 722
  response to therapy in adults with minimal lesion glomerulonephritis, 588
Pulmonary hypertension, experimental dialyser membrane reactions, 135
Purpura, weakness – arthralgia syndrome, 528
Pyrophosphate, in bone scintigraphy in dialysis patients, 431
Ranitidine, effect on renal function and parathyroid activity, 761
Recurrent fever, in familial nephropathic amyloidosis, 683
Recurrence stone formation, treatment by high fluid intake or diuretics, 743
Red cell, vitamin E and fragility, 296
Registry Report
adult report, 3–65
body mass index, 43
cardiovascular risk factors in diabetic and non-diabetic patients, 5, 69
computers, 61
data consistency, 17
dialysis equipment, 56
hepatitis, 56
malignancies, 47
modes of treatment, 8–9, 12–13
parathyroidectomy, 50
patient acceptance rates, 7, 14
patient survival
retrospective paired analysis, 28
survival on integrated therapies, 19
the Selwood analysis, 23
rare causes of death, 47
successful pregnancies, 56
transplantation
cadaver grafts, 31
cyclosporine, 33
diabetic patients, 31
fine neede aspiration biopsy, 33
graft function, 37
live donor grafts, 30
rates, 10–11, 16
Registry Report – children
paediatric report, 67–95
Rehabilitation, elderly dialysis patients, 496
Rejection, detection by urinary thromboxane B2 and β2-microglobulin, 1032
Renal autoregulation, effect of cimetidine, 765
Renal biopsy
appearances in experimental acute renal failure, 837
glomerular C3b receptor loss in allografts, 1015
monoclonal antibody studies, 666
Renal blood flow, effect of cimetidine, 765
Renal ischaemia, role in cyclosporine induced acute renal failure, 849
Renal failure, relationship between proteinuria and progression in diabetic nephropathy, 633
Renal failure, acute cyclosporine induced, 849
in an infant with partial deficiency of HPRT, 751
effect of combined propranolol and captopril in an experimental model, 837, 843
Renal failure, chronic
dietary protein restriction and progression of failure, 549, 561, 567, 600, 604
effect of ranitidine therapy, 761
fluoride metabolism, 421
growth in children, 830
hepatitis B vaccination schedule, 300
human pancreatic polypeptide and somatostatin, 614
interleukin 1 production, 825
low incidence of hyperparathyroidism in diabetic patients, 902
muscle acid/base studies, 881
naloxone infusion studies, 608
osteodystrophy, 888
protein binding of aluminium, 360
reduced clearance of somatostatin, 614
serum nickel, 241
zinc deficiency, 825
Renal function
after donor nephrectomy, 580
changes in experimental acute renal failure, 837
effect of continuous subcutaneous infusion in diabetic nephropathy, 722
investigative techniques, 771
Renal osteodystrophy
bone mineral loss, 435
in Fanconi syndrome, 756
fluoride metabolism, 421
Renal plasma flow
investigation, 772, 776
in diabetic nephropathy, 642
prior to cardiac transplantation and effect on cyclosporine nephrotoxicity, 973
Renal preservation, use of Belzer II solution, 1027
Renal structure, investigative technique, 771
Renal tubular acidosis, in diabetic nephropathy, 801
Renal tubular cells, ultrastructural changes in experimental diabetes insipidus, 732
Renal osteodystrophy aluminium effect, 399
in diabetic patients with chronic renal failure, 902
Renal vasodilatation, early diabetic nephropathy, 623
Renin
- in pregnancy induced hypertension, 808
- low values in diabetic nephropathy, 801
- response to potassium changes in essential hypertension, 81
Reverse osmosis
- effective in removing nitrates, 321
- water treatment, 119
Sediment filtration, water treatment, 113
Sepsis, experimental acute renal failure, 837
Septicaemia, elderly dialysis patients, 497, 512, 515
Sham dialysis, haemodynamic response, 156
Shear forces, 106
Shoulder pain syndrome, in patients after prolonged haemodialysis, 291
Silicone spillage, 287
Sodium
- captopril induced increase in urinary excretion, 820
- effect of dialysate sodium in catecholamines, 225
- in the distal tubule and water reabsorption, 738
Somatostatin, in chronic renal failure and dialysis, 614
Sreptozotocin, in the induction of experimental diabetes mellitus, 860
Steroid
- therapy in rapidly progressive crescentic glomerulonephritis, 594
- therapy in minimal lesion glomerulonephritis in adults, 588
Succinate
- cardiovascular effects during dialysis, 230
- metabolic effects during dialysis, 230
Sulphapyrazine, interaction with cyclosporine, 1021
Survival statistics
- children, 69
- elderly dialysis patients, 499, 513
- integrated therapies, 19
- retrospective paired analysis, 28
Systemic lupus erythematosus
- clinical findings, 712
- filtration fraction, 717
- prognostic factors in nephropathy, 717
- renal disease activity, 717
- quantification of progression of nephropathy, 717
T cell subsets
- following renal transplantation, 1037
- in Fabry's disease, 686
- monoclonal antibodies, 1037
- helper cells, 1037
T suppressor cells, 1037
Theophylline, sensitivity test following transplantation, 1037
Thromboxane, role in the transfusion effect on transplantation, 923
Transfusion, donor specific, 30
Transfusion coefficients, membrane, 100
Transplantation
- aetiology of cyclosporine nephrotoxicity, 853
- blood transfusion effect, 923
- changes in serum, 928
- clinical results, 982
- CMV infection, 936, 1021
- combined ALG and cyclosporine, 987
- complications in the donor of live donor transplantation, 911
- conversion from conventional therapy to Cys therapy, 982
- conversion from cyclosporine to conventional therapy, 992, 998
- cyclosporine, 992, 1002, 1010, 1042
- cyclosporine and lymphoproliferation, 1021
- cyclosporine nephrotoxicity, 969, 992, 998
- cyclosporine and ATG, 982
- effects of cyclosporine on prednisolone metabolism, 963
- effects of donor nephrectomy on renal function in the live donor, 574
- effect on left ventricular anatomy, 185
- erythropoietin after transplantation, 928
- glomerular C3b receptor loss in allografts, 1015
- graft rejection and membranous nephropathy, 672
- growth in children, 830
- helper T cells, 1037
- in children, 86–90
- incidence, prognosis and aetiology of de novo graft membranous nephropathy, 672
- infection, 1042
- interleukin 2 production during rejection, 1006
- investigation of renal function by radiolabelled techniques, 779
- live donors, 574, 911

1057
long term results of donor nephrectomy, 580
metabolic effects of conversion to conventional immunosuppression from cyclosporine, 1010
monoclonal antibodies, 1037, 1042
natural killer cells, 1042
peptic ulceration, 936
perfusion with Belzer II for kidney preservation, 1027
pneumatosis intestinalis, 936
polycythaemia, 928
prostaglandins and thromboxane, 923
Registry Statistics, 30–46
results in CAPD patients, 932
results with cyclosporine, 963
role of monocytes, 923
subcapsular pressure monitoring, 954
suppressor T cells, 1037
urinary prostaglandin production, 969
use of kidneys from diabetic donors, 655
T cell subsets, 1037
theophylline sensitivity test, 1037
thromboxane B2 and β2-microglobulin as indications of graft rejection, 1037
Tubular function
in hyperosmolar states in patients with diabetic nephropathy, 875
reversible changes in alcoholic patients, 866
Tubular proteinuria
in children with diabetes mellitus, 638
in diabetic nephropathy, 875
Type IV collagen, in focal sclerosis, 791
Ultrafiltration
loss by peritoneal membrane in elderly dialysis patients, 498
water treatment, 121
Ultrasound
examination of the kidney, 781
guidance of fine needle into parathyroid glands for alcohol injection, 895
Urea generation rate, in haemofiltration in children, 326
Uraemia

cyclosporine absorption, 948
effect of early protein restriction and progression to renal failure, 567
effect of dietary protein restriction, 549, 604
effect of ranitidine therapy, 761
hepatitis B vaccination schedules, 300
insulin resistance of fat cells, 725
naloxone infusion studies, 608
platelet life span, 306
responsiveness of β2-adrenoceptors, 178
Uraemia, experimental, dietary studies, 549
Ureteric ligation, experimental studies in diabetics, 860
Uric acid, disordered metabolism in partial HPRT deficiency, 751
Uric acid nephropathy, in partial HPRT deficiency, 751
Vaccination, hepatitis B in patients with renal failure, 300
Valsalva test, effect of naloxone, 190
Vascular access
blood flow in AV grafts, 262
experimental with Hickman catheters and hema-site access device, 257
hema-site vascular access device, 262
use of the biocarbon vascular access device for haemodialysis, 267
Vasculitis
associated with glomerulonephritis and hepatic cirrhosis, 677
essential mixed cryoglobulinaemia, 530
Viral infections, in haemodialysis patients, 317
Visual function, in diabetic patients on CAPD, 330
Vitamin D
effect of 1αOH3D3 on plasma aluminium, 390
1,25(OH)2D3 cholecalciferol in Fanconi syndrome, 756
24,25(OH)2D3 in Fanconi syndrome, 756
25(OH)D3 cholecalciferol in Fancconi syndrome, 756
influence on progression of renal failure, 270
lower requirement in diabetic patients with chronic renal failure, 902
metabolism in Fancconi syndrome, 756
status in relation to bone mineral loss, 435
Vitamin D metabolites
bone turnover, 415
osteoblastic and osteoclastic surfaces, 415

1058
Vitamin E, supplementation, 296

Water, excess nitrates aggravating anaemia, 321
Water quality, standards, 122
Water reabsorption
distal tubular sodium, 738
during maximal water diuresis, 738
Water softening, water treatment, 114

Water treatment
for nitrate removal, 162
requirement for dialysate preparation, 111–128

Zinc deficiency
effects of cell mediated immunity, 825
effects of supplementation on cell mediated immunity, 825